Roche Holding AG
RHHBY
Updated: 23/09/2026, 13:58:18
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
No summaries found.
- Share price
- $55.66
- Market cap
- $354.81B
- Exchange
- OTC
- Currency
- USD
- CEO
- Thomas Schinecker
- Employees
- 103,249
- IPO date
- 20/08/2003
- Beta
- 0.347
- Last dividend
- $0.00
- Day range
- $54.78 – $55.77
- 52-week range
- $39.50 – $60.85
- 1-day performance
- 0.65%
- 1-year performance
- 40.91%
- Current drawdown (1Y)
- -8.53%
- CIK
- N/A
- CUSIP
- 771195104
- ISIN
- US7711951043
- Created
- 07/12/2025, 13:58:52
- Last update
- 23/09/2026, 13:58:18
Track Roche Holding AG with an AI analyst
See which prediction-market events move RHHBY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Nurix Therapeutics Deal With Roche Is Worth Betting On
Seeking Alpha • STOCK • 11/06/2026, 11:48:54
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know
Seeking Alpha • STOCK • 10/06/2026, 15:44:23
Roche sticks to German investment after Eli Lilly cuts
Reuters • STOCK • 09/06/2026, 05:39:24
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Seeking Alpha • STOCK • 08/06/2026, 20:48:30
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Barrons • STOCK • 08/06/2026, 12:08:00
Nurix Therapeutics Stock Pops on Roche Partnership
Schaeffers Research • STOCK • 08/06/2026, 11:45:54
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Reuters • STOCK • 08/06/2026, 05:51:08
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
WSJ • STOCK • 08/06/2026, 03:47:00
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
GlobeNewsWire • STOCK • 08/06/2026, 03:00:00
Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial
Reuters • STOCK • 05/06/2026, 21:31:26
Zealand touts promising tolerability data for obesity drug in mid-stage study
Reuters • STOCK • 05/06/2026, 18:47:23
Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection
PRNewsWire • STOCK • 04/06/2026, 13:33:00